181 results on '"Momma, Tetsuo"'
Search Results
2. Secondary bladder cancer during long-term follow-up after iodine-125 permanent seed implantation for localized prostate cancer
3. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
4. Trimodality Therapy With Iodine-125 Brachytherapy, External Beam Radiation Therapy, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer: Results of a Multicenter, Randomized Phase 3 Trial (TRIP/TRIGU0907)
5. Quantitative analysis of genitourinary toxicity after iodine-125 brachytherapy for localized prostate cancer: Followup of the International Prostate Symptom Score and Overactive Bladder Symptom Score
6. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
7. Results of a multicenter, randomized, phase 3 trial of trimodality therapy with I-125 brachytherapy, external beam radiation therapy, and long- versus short-term androgen deprivation therapy for localized high-risk prostate cancer (TRIP/TRIGU0907).
8. External Validation of the MSKCC and IMDC Risk Models in Patients Treated with Targeted Therapy as a First-line and Subsequent Second-line Treatment: A Japanese Multi-institutional Study
9. Impact of an Adjuvant Chemotherapeutic Regimen on the Clinical Outcome in High Risk Patients with Upper Tract Urothelial Carcinoma: A Japanese Multi-Institution Experience
10. Outcomes following iodine-125 prostate brachytherapy with or without neoadjuvant androgen deprivation
11. Impact of MRI-based postimplant dosimetric assessment in prostate brachytherapy using contrast-enhanced T1-weighted images
12. A Multi-Institutional Validation of the Prognostic Value of the Neutrophil-to-Lymphocyte Ratio for Upper Tract Urothelial Carcinoma Treated with Radical Nephroureterectomy
13. Independent Predictors for Bladder Outcomes after Treatment of Intravesical Recurrence following Radical Nephroureterectomy in Patients with Primary Upper Tract Urothelial Carcinoma
14. Metastatic Behavior of Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy: Association with Primary Tumor Location
15. IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY: MP27-18
16. EXTERNAL VALIDATION OF PROGNOSTIC IMPACT OF PATIENT AGE AND GENDER IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY: PROPOSED NEW PERSPECTIVE OF GENDER-ADJUSTED AGE IN UPPER TRACT UROTHELIAL CARCINOMA: PD13-12
17. PD13-01 NOVEL SIMULATING MODEL OF THE SURVEILLANCE DURATION AFTER LOW DOSE RATE BRACHYTHERAPY FOR PROSTATE CANCER PATIENTS: AN INDIVIDUALIZED RISK-BASED METHOD APPLYING WEIBULL DISTRIBUTIONS
18. PSOR10 Presentation Time: 12:45 PM: Evaluation of Toxicity for a Randomized Trial of Tri-Modality Therapy with Iodine-125 Brachytherapy, External Beam Radiation, and Short- or Long-Term Androgen Deprivation Therapy for High-Risk Localized Prostate Cancer (TRIP Trial)
19. THE PREDICTIVE VALUE OF C-REACTIVE PROTEIN FOR PROGNOSIS IN PATIENTS WITH METASTATIC UPPER TRACT UROTHELIAL CARCINOMA TREATED WITH CISPLATIN-BASED CHEMOTHERAPY FOLLOWING RADICAL NEPHROURETERECTOMY: MULTI-INSTITUTIONAL STUDY: MP77-19
20. Serial changes of international prostate symptom score following I-125 prostate brachytherapy
21. Comparison of intraoperative ultrasound with postimplant computed tomography–dosimetric values at Day 1 and Day 30 after prostate brachytherapy
22. Acute urinary morbidity following I-125 prostate brachytherapy
23. Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
24. Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: the experience of Japanese multi-institutions
25. PREDICTIVE VALUE OF POSITIVE URINE CYTOLOGY FOR PROGNOSIS IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY: 399
26. CHARACTERISTICS AND OUTCOME IN METASTATIC UPPER TRACT UROTHELIAL CARCINOMA FOLLOWING RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL EXPERIENCE: 398
27. The predictive value of positive urine cytology for outcomes following radical nephroureterectomy in patients with primary upper tract urothelial carcinoma: A multi-institutional study
28. Comparison of prostate verification with implanted gold markers in tissue surrounding the prostate and pelvic bony anatomy for external beam radiation therapy following low-dose-rate brachytherapy: a prospective clinical trial
29. Rectal Morbidity Following I-125 Prostate Brachytherapy in Relation to Dosimetry
30. Predictive Factors of Acute Urinary Retention Requiring Catheterization Following 125I Prostate Brachytherapy
31. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy
32. Metanephric Adenoma Treated with Laparoscopic Nephrectomy
33. Brachytherapy for prostate cancer in Japan
34. Sub-classification of patients with intermediate-risk metastatic renal cell carcinoma treated with targeted therapy
35. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma
36. Impact of Second-Line Targeted Therapy Dose Intensity on Patients With Metastatic Renal Cell Carcinoma
37. MP78-12 DOES NEOADJUVANT CHEMOTHERAPY WITH GEMCITABINE AND CISPLATIN IN BLADDER CANCER INCREASE THE COMPLICATIONS AT RADICAL CYSTECTOMY IN HIGH AGE PATIENTS?
38. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer
39. Plan reproducibility of intraoperatively custom-built linked seeds compared to loose seeds for prostate brachytherapy
40. Significance of a frozen section analysis of the ureteral margin in bladder cancer patients treated with radical cystectomy and neoadjuvant chemotherapy
41. Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model11Dr. Mizuno reports grants from The Japan Agency for Medical Research and Development (AMED), personal fees from Pfizer, grants and personal fees from Novartis, during the conduct of the study. Dr. Mikami reports grants from The Japan Agency for Medical Research and Development (AMED) during the conduct of the study. Dr. Oya reports grants from The Japan Agency for Medical Research and Development (AMED), grants and personal fees from Pfizer, grants and personal fees from Novartis, personal fees from Bayer, during the conduct of the study. No potential conflicts of interest were disclosed by the other authors.
42. Impact of inflammatory marker levels one month after the first-line targeted therapy initiation on progression-free survival prediction in patients with metastatic clear cell renal cell carcinoma.
43. A case of synchronous triple primary carcinomas of the kidney, bladder and prostate
44. Local Recurrence of Micropapillary Bladder Tumor after Radical Cystectomy : Successful Treatment with Radiation Therapy : A Case Report
45. Effect of reclassification of the IMDC model in patients with metastatic renal cell carcinoma treated with targeted therapy in the first-line and second-line settings
46. PD13-12 EXTERNAL VALIDATION OF PROGNOSTIC IMPACT OF PATIENT AGE AND GENDER IN PATIENTS TREATED WITH RADICAL NEPHROURETERECTOMY: PROPOSED NEW PERSPECTIVE OF GENDER-ADJUSTED AGE IN UPPER TRACT UROTHELIAL CARCINOMA
47. MP27-18 IMPACT OF MAXIMUM TUMOR DIAMETER ADJUSTED BY PRIMARY TUMOR LOCATION IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA MANAGED BY RADICAL NEPHROURETERECTOMY: THE MULTI-INSTITUTIONAL STUDY
48. Comparison of genitourinary and gastrointestinal toxicity among four radiotherapy modalities for prostate cancer: Conventional radiotherapy, intensity-modulated radiotherapy, and permanent iodine-125 implantation with or without external beam radiotherapy
49. Multi-institutional retrospective analysis of learning curves on dosimetry and operation time before and after introduction of intraoperatively built custom-linked seeds in prostate brachytherapy
50. Prostate cancer with high serum level of CEA and CA19-9: a case report
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.